Superior retinal fluid resolution vs aflibercept^1,2

• Beovu outperformed aflibercept, with significantly fewer patients with IRF and/or SRF at Weeks 16 and 48¹
• The difference was maintained at Week 96²

Early superior CST reductions vs aflibercept^1,2

• Beovu outperformed aflibercept with superior CST reductions at Week 16, with similar results observed at Week 48¹*
• The difference was maintained at Week 96 (p=0.0115 in HAWK, p<0.0001 in HARRIER)^2†

The primary efficacy endpoint in both studies was non-inferiority in mean BCVA change from baseline to Week 48 as measured by ETDRS. The primary endpoint was met in both studies.¹
*Secondary endpoint in HAWK and HARRIER, confirmatory analysis in HAWK only (1-sided p values for superiority of Beovu).^1,2
†Secondary endpoints in HAWK and HARRIER; 2-sided p values.¹

BCVA, best corrected visual acuity; CST, central subfield thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; IRF, intraretinal fluid; LS, least squares; SRF, subretinal fluid.

References

1. Dugel PU et al. Ophthalmology. 2020; 127: 72–84.
2. Novartis data on file. BRODOF20-001 Core Data Sheet.